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Abstract
Purpose—To investigate end-of-life care for Medicaid, Medicare, and dually eligible 
beneficiaries dying of cancer in Texas.
Methods—We analyzed the Texas Cancer Registry (TCR)-Medicaid and TCR-Medicare linked 
databases’ claims data for 69,572 patients dying of cancer in Texas from 2000–2008. We 
conducted regression models in adjusted analyses of cancer-directed and acute care and total costs 
of care (in 2014 dollars) in the last 30 days of life.
Results—Medicaid patients were more likely to receive chemotherapy and radiation therapy. 
Medicaid patients were more likely to have >1 emergency room (ER) (OR=5.27, 95% CI: 4.76–
5.84), and were less likely to enroll in hospice (OR=0.59, 95% CI: 0.55–0.63) than Medicare 
patients. Dual eligibles were more likely to have >1 ER visit than Medicare-only beneficiaries 
(OR=1.19, 95% CI: 1.07–1.33). Black and Hispanic patients were more likely to experience > 1 
ER visit and >1 hospitalization than whites. Costs were higher for non-white Medicare , Medicaid, 
and dually eligible patients compared to white Medicare enrollees.
Conclusion—Variation in acute care utilization and costs by race and payer suggest efforts are 
needed to address palliative care coordination at the end of life for Medicaid and dually eligible 
beneficiaries and minority patients dying of cancer.
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INTRODUCTION
Studies of insurance claims data have identified trends of aggressive end-of-life care for 
patients dying of cancer, specifically with respect to utilization of chemotherapy, emergency 
room (ER) care, hospitalization, lack of hospice use, and radiation therapy.1–3 These 
findings led to development of claims-based indicators to assess the intensity of care at the 
end-of-life for patients dying of cancer.4,5 Most of these studies have focused on patients 
enrolled in fee-for-service Medicare whose claims data are linked to the National Cancer 
Institute’s Surveillance, Epidemiology, and End Results (SEER) registries which provide 
cancer-related clinical information. However, a recent study linking cancer registry data in 
New York and California to Medicaid claims files showed that Medicaid patients had 
significantly lower hospice enrollment compared to their same-state Medicare counterparts.6 
There are few other published studies regarding cancer-related care and outcomes for 
Medicaid patients in general, but some data do indicate that a high proportion of Medicaid 
enrollees present with late-stage cancer at diagnosis which is often incurable,7–9 raising the 
importance of quality end-of-life cancer care for Medicaid patients.
A focus on Medicaid care delivery bears particular contemporary policy relevance given 
that, as of this writing (February 2015), Medicaid expansion is occurring in 29 states and the 
District of Columbia and its expansion is under debate in 7 other states. It is the primary 
payer for health care for many of the nation’s most vulnerable populations (i.e. low-income 
and largely minority).10 There is also current policy relevance to understanding care 
delivery and outcomes for patients who are dually eligible for Medicare and Medicaid. 
Dual-eligible beneficiaries are comprised of those who are disabled, chronically ill, or 
require admission to long-term care facilities and fall below an income threshold such that 
they are eligible for both programs to pay for their medical care. Dually eligible patients 
present challenges of both care and financing coordination because they are often medically 
complicated and their health care reimbursements have to be coordinated between federal 
and state payers.11 While dual-eligible patients comprise one-fifth of those covered by each 
payer, they account for approximately one-third of expenditures for Medicaid and Medicare, 
respectively.12 Some studies have shown that dually eligible patients have disparate cancer 
care utilization and poorer survival than cancer patients enrolled upon Medicare alone.13
Recently the Texas Cancer Registry has linked cancer-specific clinical data to Medicaid and 
Medicare claims files for analysis of outcomes, utilization, and costs of cancer care for the 
citizens of Texas. Texas’ database offers a robust and nationally relevant population sample, 
as it is the second most populous state in the US and one whose population is diverse and 
currently represents the future predicted racial/ethnic diversity of the US by 2040.14,15 The 
aims of this study are to ascertain differences in and costs of end-of-life care among patients 
dying of cancer in Texas with respect to whether a patient was enrolled in Medicaid and/or 
Medicare. We hypothesized that Medicaid and dually eligible patients would have higher 
rates of poor quality end-of-life care indicators (e.g., lack of hospice enrollment, more acute 
care utilization, receipt of chemotherapy in the last 30 days of life, etc.) than their Medicare 
counterparts.
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METHODS
Data sources and cohort definition
We conducted this analysis using the Texas Cancer Registry (TCR)-Medicare and TCR-
Medicaid linked databases. In Texas, 12% of citizens are Medicare beneficiaries and 19% 
are Medicaid enrollees. Among these Texans who receive publicly-funded health care, over 
640,000 were dually eligible for both Medicare and Medicaid in 2010.16 TCR files are 
linked to Medicare and Medicaid claims files using probabilistic linkage methods that 
protect individual patient privacy to obtain utilization data. All data were de-identified such 
that no protected health information could be linked to individual patients, and the MD 
Anderson Cancer Center’s institutional review board exempted this study.
We identified 69,572 patients who died as a result of breast, colorectal, lung, melanoma, 
pancreatic, and prostate cancers between January 1, 2000 and December 31, 2008. Of these, 
3561 were fee-for-service Medicaid enrollees, 56,875 were Medicare beneficiaries (who 
were not dually eligible), and 9136 were dually eligible for both Medicaid and Medicare. 
Payer status was valid for the final 60 days of life. Medicare patients who were dually 
eligible for Medicaid were identified by an encrypted beneficiary ID linked with Medicaid 
monthly enrollment status abstracted from Medicaid Analytic Extracts (MAX) Personal 
Summary files. Date of death was determined from TCR. Patients’ causes of death were 
determined using the 9th and 10th revisions of the International Classification of Disease 
Codes (ICD-9 and ICD-10). End-of-life health care utilization and cost data were examined 
for patients dying of these six cancers because these malignancies comprise over 60% of 
cancer causes of death in the US.17 Table 1 shows the criteria for cohort development for 
this study.
End of life care utilization
We analyzed claims data to assess for receipt of various aspects of oncology, acute, and end 
of life care utilization in the last 30 days of life in this cohort. Receipt of radiation therapy 
(RT) was identified using Current Procedural Terminology (CPT) codes to confirm RT 
delivery (see appendix). Receipt of chemotherapy was also determined by presence of CPT 
chemotherapy codes (codes in appendix).
We determined whether a patient had an ER visit in the study window by using the 
following ER service codes (provided in appendix), and the number of ER days were 
determined by number of dates with one of these service codes present. Similarly the 
number of hospital days was determined by the number of hospital (inpatient) service dates, 
including intensive care unit (ICU) service dates in the MEDPAR claims file for Medicare 
and the Medicaid Analytic Extract Inpatient Claims file. Hospice care was identified as any 
hospice admission and/or service date in the hospice claims file for Medicare or in the 
Medicaid file.
Costs
We calculated costs from the payer’s perspective (total amount reimbursed by Medicaid and 
Medicare) and included all costs incurred in the 30 day window before death except for 
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outpatient prescription drug costs. We did not include prescription drug costs because 
Medicare Part D data were only available starting in 2007. Costs were normalized to the 
2014 dollar using the Consumer Price Index-Medical Care services from the Bureau of 
Labor Statistics and the US Medicaid inflation rate.18,19
Statistical analyses
Statistical analyses were conducted with SAS Systems software for Windows (version 9.2) 
and STATA (version 13.0). The unadjusted association of whether the patient was a 
beneficiary of Medicaid, Medicare, or dually eligible with each potential socio-demographic 
variable, and health care utilization outcomes was assessed with χ2 tests for categorical 
variables. All p-values were two-sided, and a threshold of 0.05 was used to determine 
significance. Multivariable logistic regression models were used to examine independent 
association between explanatory variables and health care utilization patterns. In addition to 
type of publicly-funded insurance coverage, other explanatory variables included: sex, race/
ethnicity (non-Hispanic white, non-Hispanic black, Hispanic, other), cancer type causing 
death, and whether the patient had distantly metastatic cancer at the time of cancer 
diagnosis. We also adjusted for co-morbidity by computing claim-based comorbidity 
weights based on the National Cancer Institute’s Statistical Analysis System (SAS) 
algorithm which uses diagnosis, surgery, and HCPCS codes abstracted from the patient’s 
hospital claims and carrier claims submitted to either Medicare or Medicaid one year prior 
to the date of death, which computes a Charlson co-morbidity index score.20 We adjusted 
for geographic variation in both medical costs and medical care availability within Texas by 
including Health Services Area (HSA) fixed effect in adjusted models. The county and HSA 
crosswalk was obtained from the Texas Department of Health and Human Services.21 Both 
the Hosmer Lemeshow and the Pearson’s correlation tests were conducted for model fit 
assessments, and showed no systematic patterns in the residuals across predictors. Cost data 
were analyzed using the method of extended estimating equations for analyzing highly 
skewed costs data.22 The approach adopts power variance ( ; link 
function = (μλ−1)/λ, if λ≠0) to derive robust estimations when no specific distribution for the 
outcome measure is identified.
RESULTS
Characteristics of the study cohort
The characteristics of the study cohort are shown in Table 2. As expected, the Medicaid 
patients were younger than the Medicare and dually eligible patients. Less than half of the 
Medicaid and dually eligible patients were non-Hispanic white, whereas 80% of the 
Medicare patients were non-Hispanic white. Hispanics comprised 24% and 30% of the 
Medicaid and dually eligible cohorts, respectively; and non-Hispanic black patients 
comprised 25% and 22% of the Medicaid and dually eligible cohorts, respectively. Sixty 
percent of the Medicaid patients had distantly metastatic cancer at the time of diagnosis 
compared to 39% and 41%, respectively, of the Medicare and dually eligible cohorts. Over 
half of Medicaid enrollees had no co-morbidities compared to 37% and 23% of the 
Medicare and dually eligible patients, respectively.
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Chemotherapy and radiation therapy utilization in the last 30 days of life
A significantly higher proportion of Medicaid patients received chemotherapy in the last 30 
days of life as well as in the last 14 days of life compared to Medicare and dually eligible 
patients (Table 3). Similarly, almost double the percentage of Medicaid patients received 
radiation therapy in the last 30 days of life compared to Medicare and dually eligible 
patients. The results of multivariable analyses adjusting for socio-demographic, health 
services, and clinical characteristics are shown in Table 3. Medicaid patients were 
significantly more likely to receive chemotherapy in the last 14 days and 30 days of life, 
respectively (OR=1.58, 95% CI: 1.32–1.89 for chemotherapy in the last 14 days; and 
OR=1.72, 95% CI: 1.53–1.94 for the last 30 days) compared to Medicare or dually eligible 
patients. Similarly, Medicaid patients were also more likely to undergo radiation therapy in 
the last 14 days and 30 days of life, respectively. Dually eligible patients were significantly 
less likely to receive radiation therapy in the final month of life than their Medicare-only 
counterparts.
Acute care utilization in the last 30 days of life
Among Medicaid patients dying of cancer in this cohort, 20% had >1 ER visit in the last 30 
days of life. Adjusted analyses (Table 3) confirmed that Medicaid patients were more likely 
to have >1 emergency room visit in the final 30 days of life than their Medicare counterparts 
(OR=5.27, 95% CI: 4.76–5.84) Dually eligible patients were also more likely to have > 1 
ER visit than Medicare-only patients (OR = 1.19; 95% CI: 1.07–1.33). Dually eligible 
patients were significantly less likely to have > 1 hospital admission in the last 30 days of 
life compared to Medicare-only patients (OR=0.90, 95% CI: 0.84–0.97).
Multivariable analyses also revealed that black and Hispanic patients were more likely to 
experience > 1 ER visit in the last 30 days of life than white patients. Non-white race was 
also associated with a significantly greater likelihood of having > 1 hospital admission it he 
final 30 days of life (Table 3).
Hospice utilization in the last 30 days of life
Among Medicaid enrollees, 49% did not have hospice enrollment within the final 30 days of 
life (Table 3) compared to 34% of Medicare patients and 35% of dually eligible patients, 
respectively. In multivariable analysis adjusting for other characteristics (Table 3), Medicaid 
enrollees were significantly less likely to enroll in hospice in their final 30 days of life 
compared to Medicare and dually eligible patients. Dually eligible patients were more likely 
than Medicare-only enrollees to enroll in hospice in the final 30 days of life. Non-white race 
was associated with significantly decreased likelihood of hospice enrollment.
Differences in costs
We performed multivariable analyses of costs controlling for year of death and health 
service area (Table 4). We identified a significant interaction between race and payer status 
(e.g, Medicaid, Medicare, or dually eligible) regarding association with costs, likely 
attributable to the differences in acute care utilization as described above. With white 
Medicare enrollees as the reference group, expenditures were significantly higher for non-
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white Medicare, Medicaid, and dually eligible patients. Expenditures were significantly 
lower for dually eligible white enrollees compared to white Medicare enrollees.
DISCUSSION
Medicaid patients dying of cancer experienced more aggressive cancer-directed therapy and 
more emergency room utilization at the end of life than their Medicare-insured counterparts. 
Dually eligible patients also had more intense emergency room use at the end of life than 
Medicare-only patients. Hospice enrollment was significantly underutilized among Medicaid 
patients and racial/ethnic minority patients of any payer status. Regardless of payer, racial/
ethnic minority patients experienced higher acute care utilization in the last 30 days of life 
and strongly influenced the observed costs of care reimbursed by both Medicaid and 
Medicare whether patients were beneficiaries of one or both.
The observed proportions of Medicare-enrolled (including dually eligible enrollees) patients 
receiving chemotherapy in the final month of life in this analysis are similar to those seen by 
other investigators who have investigated this in other Medicare cohorts.1,5 However, the 
proportion of Medicaid patients who received chemotherapy in the last month of life was 
approximately double that seen for reported Medicare-only cohorts. The proportion of Texas 
Medicare enrollees receiving radiation therapy in the last month of life was slightly lower 
than observed in another large, multi-state cohort of Medicare enrollees.3 In contrast, the 
proportion of Medicaid patients receiving radiation therapy in the last month of life was 
slightly higher. The significance of the proportion receiving radiation therapy is not clear, 
and it should be noted that it has not itself been deemed a quality indicator of end-of-life 
care. Some studies suggest proportional underuse of radiation therapy,23 while others 
suggest high intensity of radiation therapy use among those who do receive radiation therapy 
at the end of life.3,24 Understanding of radiation therapy use is relevant to end-of-life care, 
but it is a subject that needs further study. The explanation for higher proportional utilization 
of cancer-directed therapies, in general, among Medicaid enrollees may relate to the fact that 
Medicaid patients were younger and had fewer co-morbidities than Medicare and dually 
eligible patients, which may have influenced decision making about cancer-directed therapy 
administration toward treating these patients more aggressively.
The higher utilization of emergency care among Medicaid enrollees, and minority patients 
regardless of payer, suggests that patients from vulnerable populations may not be receiving 
optimal supportive care at the end of life. Likely related to this finding, we observed 
significantly less hospice utilization among Medicaid enrollees and minorities. Others have 
observed similar hospice utilization trends among Medicaid patients in other states.6 One 
explanation could be lack of access to hospice care, and we did observe that rurally residing 
patients were less likely to enroll in hospice (data not shown). Other investigators have 
documented that racial and ethnic minorities dying of cancer were less likely to enroll in 
hospice services,25 and this disparity may be due in some part to patient preferences 
regarding the discontinuation of cancer-directed therapy.26 In our cohort, it is also possible 
that lack of knowledge of hospice services and benefits, cultural barriers, or language 
barriers may have also impeded hospice enrollment among Medicaid patients. However, 
efforts can and should be made to address these barriers and coordinate appropriate 
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supportive care for Medicaid patients, such as was done for Medicaid enrollees in Maryland 
with use of a palliative care case management program that significantly decreased acute 
care utilization at the end of life for Medicaid beneficiaries.27
Patients in our study who were dually eligible for both Medicare and Medicaid had similar 
end-of-life chemotherapy utilization as that observed for patients enrolled in Medicare only, 
but were less likely to receive radiation therapy. There are few data regarding cancer-
directed therapy utilization for dual eligibles. However, Bradley and colleagues13 showed 
that dually eligible beneficiaries in Michigan were less likely to undergo curative surgery for 
lung cancer than Medicare counterparts, even when controlling for co-morbidities. The 
relatively high observed costs for non-white dually eligible beneficiaries in our cohort are 
likely related to the high proportion of dually eligible patients with multiple comorbidities 
(Table 2) combined with the high acute care utilization observed for non-white patients 
regardless of payer. Relatedly, the lower expenditures observed for white dually eligible 
patients is likely related to the lower likelihood of > 1 hospital admission among white 
patients. In other words, the racial/disparities in acute care utilization exerted the strongest 
influence among dually eligible patients; i.e., costs were actually significantly lower for 
white dual eligibles compared to all other groups but significantly higher for non-white dual 
eligible compared to all other groups. These findings signal a need for targeted palliative 
care access and coordination efforts for terminally ill, dually eligible minority patients.
Our study has inherent limitations to retrospective cohort analyses using registry data linked 
to claims data. Chief among them is that patient and provider preference information is not 
available in these databases. We also acknowledge that use of death as the reference point 
and looking retrospectively at care is controversial.28 It has been established that physicians 
cannot accurately predict survival times for individual patients, thus limiting the ability to 
make inferences regarding whether end of life care was appropriate or not. However, we 
would like to note that other investigators have used death as an investigative reference 
point to study acute care and cancer-directed therapy quality metrics for other population 
based cohorts.1,4,29 We also cannot glean any information in this database regarding which 
patients may have low English proficiency and thus cannot ascertain to what extent that may 
influence treatment utilization, especially in a cohort with a large proportion of Hispanic 
patients such as ours.
In conclusion, our study has identified that patients dying of cancer and who were enrolled 
upon Medicaid were more likely to receive cancer-directed therapy and more likely to utilize 
emergency services in the last 30 days of life than Medicare. Dually eligible beneficiaries 
were also more likely to have more than one emergency room visit in the last month of life, 
but costs for these patients were largely driven by observed racial differences in acute care 
utilization. Our analyses revealed that minority patients, regardless of payer status, were 
more likely to experience more intensive acute care utilization and less likely to enroll in 
hospice care in the final 30 days of life and that their care was correspondingly significantly 
more expensive. Efforts are needed to address palliative care coordination at the end of life 
for Medicaid enrollees and minority patients dying of cancer.
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